Eli Lilly’s Olumiant (baricitinib) Receives FDA Approval for Moderately-to-Severely Active Rheumatoid Arthritis (RA) in Adults

IBRI Signs a License Agreement with Eli Lilly to Access its Fab Phage Display Library


  • The approval is based on P-III RA-BEACON study results assessing Olumiant vs PBO in 527 patients with inadequate response or intolerance to one or more TNF inhibitor therapies
  • P-III RA-BEACON study results: ACR20 (49% vs 27%) physical function based on the Health Assessment Questionnaire Disability Index (HAQ-DI) before/ after treatment (1.71, 1.78/ 1.31, 1.59)
  • Olumiant (baricitinib, 2mg) is an oral drug indicated for patients with RA who have inadequate response to TNF antagonist therapies and is approved in 50 countries including the US, EU and Japan. In Dec,2009 Lilly and Incyte collaborated to develop and commercialize Olumiant for inflammatory and autoimmune diseases

Click here to read full press release/ article | Ref: Eli Lilly | Image: WSJ